STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo (STO:ORX) confirms the announcement made by ProStrakan Group plc (LSE:PSK), Orexo’s partner for Abstral® in Europe and North America, that it has received a Marketing Authorisation from the German regulatory authority, BfArM for Abstral (for breakthrough cancer pain). ProStrakan now plans to launch Abstral in Germany and the UK in the first few weeks of 2009, with further launches across Europe during the year. As a result of the approval, Orexo will receive a milestone payment of EUR 650 000.
